NCT01488409View on ClinicalTrials.gov

Effects of Acipimox on Mitochondrial Function in Obesity

PHASE2CompletedINTERVENTIONAL
Enrollment

39

Participants

Timeline

Start Date

May 31, 2012

Primary Completion Date

January 31, 2015

Study Completion Date

January 31, 2015

Conditions
Abdominal ObesityInsulin ResistanceHypertriglyceridemia
Interventions
DRUG

Acipimox

250 mg by mouth (PO) three times daily

DRUG

Placebo

0 mg by mouth (PO) three times daily

Trial Locations (1)

02114

Massachusetts General Hospital, Boston

All Listed Sponsors
collaborator

American Diabetes Association

OTHER

lead

Massachusetts General Hospital

OTHER

NCT01488409 - Effects of Acipimox on Mitochondrial Function in Obesity | Biotech Hunter | Biotech Hunter